Adaptive Biotechnologies (ADPT) Competitors $11.74 -0.06 (-0.51%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$11.55 -0.19 (-1.62%) As of 07/7/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADPT vs. TWST, TXG, VCYT, ELAN, RVMD, LEGN, GRFS, TGTX, NUVL, and LNTHShould you be buying Adaptive Biotechnologies stock or one of its competitors? The main competitors of Adaptive Biotechnologies include Twist Bioscience (TWST), 10x Genomics (TXG), Veracyte (VCYT), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), and Lantheus (LNTH). These companies are all part of the "medical" sector. Adaptive Biotechnologies vs. Its Competitors Twist Bioscience 10x Genomics Veracyte Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Nuvalent Lantheus Adaptive Biotechnologies (NASDAQ:ADPT) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Do analysts prefer ADPT or TWST? Adaptive Biotechnologies currently has a consensus price target of $10.57, indicating a potential downside of 9.95%. Twist Bioscience has a consensus price target of $50.40, indicating a potential upside of 41.61%. Given Twist Bioscience's higher possible upside, analysts clearly believe Twist Bioscience is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Does the media refer more to ADPT or TWST? In the previous week, Adaptive Biotechnologies and Adaptive Biotechnologies both had 7 articles in the media. Twist Bioscience's average media sentiment score of 1.04 beat Adaptive Biotechnologies' score of 0.50 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Twist Bioscience 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ADPT or TWST? Adaptive Biotechnologies has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 2.41, meaning that its stock price is 141% more volatile than the S&P 500. Do institutionals & insiders believe in ADPT or TWST? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 3.0% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is ADPT or TWST more profitable? Twist Bioscience has a net margin of -54.98% compared to Adaptive Biotechnologies' net margin of -74.84%. Twist Bioscience's return on equity of -33.48% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-74.84% -62.79% -24.55% Twist Bioscience -54.98%-33.48%-25.34% Which has higher earnings and valuation, ADPT or TWST? Adaptive Biotechnologies has higher earnings, but lower revenue than Twist Bioscience. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M9.97-$159.49M-$0.96-12.23Twist Bioscience$312.97M6.81-$208.73M-$3.25-10.95 SummaryTwist Bioscience beats Adaptive Biotechnologies on 8 of the 15 factors compared between the two stocks. Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADPT vs. The Competition Export to ExcelMetricAdaptive BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.79B$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.08%P/E Ratio-12.2320.3027.1920.04Price / Sales9.97250.25413.81108.84Price / CashN/A41.7026.2128.59Price / Book8.577.397.925.55Net Income-$159.49M-$55.04M$3.17B$248.49M7 Day Performance4.92%2.51%1.78%4.87%1 Month Performance16.35%-0.21%1.26%6.63%1 Year Performance225.21%3.41%33.30%20.38% Adaptive Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADPTAdaptive Biotechnologies3.4104 of 5 stars$11.74-0.5%$10.57-10.0%+231.6%$1.79B$178.96M-12.23790TWSTTwist Bioscience4.5244 of 5 stars$36.79+2.4%$50.40+37.0%-26.6%$2.15B$312.97M0.00990News CoveragePositive NewsTXG10x Genomics4.9104 of 5 stars$11.58-1.3%$14.96+29.2%-36.3%$1.44B$610.78M0.001,240Positive NewsVCYTVeracyte3.7485 of 5 stars$27.03-1.3%$40.90+51.3%+22.3%$2.14B$445.76M30.09790Positive NewsELANElanco Animal Health2.3411 of 5 stars$14.29flat$15.17+6.1%+1.8%$7.10B$4.44B15.209,000Analyst UpgradeRVMDRevolution Medicines4.5603 of 5 stars$36.79-0.3%$67.58+83.7%-2.3%$6.88B$11.58M0.00250LEGNLegend Biotech3.0308 of 5 stars$35.49+2.5%$76.20+114.7%-22.5%$6.36B$627.24M0.002,609GRFSGrifols4.0704 of 5 stars$9.04+2.0%$10.30+13.9%+26.0%$6.09B$7.81B0.0023,822News CoverageAnalyst UpgradeTGTXTG Therapeutics3.8586 of 5 stars$35.99-2.0%$40.80+13.4%+89.3%$5.83B$329M153.00290NUVLNuvalent3.7272 of 5 stars$76.30-4.2%$119.60+56.7%+6.9%$5.72BN/A0.0040LNTHLantheus4.4117 of 5 stars$81.86+0.5%$130.50+59.4%+0.4%$5.64B$1.53B14.22700 Related Companies and Tools Related Companies Twist Bioscience Competitors 10x Genomics Competitors Veracyte Competitors Elanco Animal Health Competitors Revolution Medicines Competitors Legend Biotech Competitors Grifols Competitors TG Therapeutics Competitors Nuvalent Competitors Lantheus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADPT) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
